Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $3.9 billion.

  • United Therapeutics' Non-Current Assets rose 2351.81% to $3.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 billion, marking a year-over-year increase of 1637.65%. This contributed to the annual value of $3.5 billion for FY2024, which is 348.17% down from last year.
  • As of Q3 2025, United Therapeutics' Non-Current Assets stood at $3.9 billion, which was up 2351.81% from $4.1 billion recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Non-Current Assets ranged from a high of $4.1 billion in Q2 2025 and a low of $2.5 billion during Q2 2021
  • Moreover, its 5-year median value for Non-Current Assets was $3.1 billion (2024), whereas its average is $3.2 billion.
  • In the last 5 years, United Therapeutics' Non-Current Assets soared by 3572.55% in 2023 and then tumbled by 1239.94% in 2024.
  • United Therapeutics' Non-Current Assets (Quarter) stood at $2.8 billion in 2021, then decreased by 6.37% to $2.7 billion in 2022, then surged by 35.73% to $3.6 billion in 2023, then dropped by 3.48% to $3.5 billion in 2024, then increased by 10.52% to $3.9 billion in 2025.
  • Its Non-Current Assets stands at $3.9 billion for Q3 2025, versus $4.1 billion for Q2 2025 and $3.8 billion for Q1 2025.